News | January 05, 2023
Yaral Pharma launches diclofenac epolamine topical system 1.3%
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Acquisitions have the potential to add at least $1 billion in sales by 2028
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The strategic acquirer maintains a nationwide presence in the LTC pharmacy space
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Subscribe To Our Newsletter & Stay Updated
